Aim Bulletin
Sareum shares jump on cancer drug licensing deal
Shares in AIM-listed biotech group Sareum jumped by a fifth on Tuesday after its co-development partner for cancer treatment SRA737 signed a commercialisation licence agreement with a US biopharma company.
R&Q confirms retirement of founder Alan Quilter
R&Q Insurance Holdings announced the retirement of Alan Quilter, its group head of programme management, on Tuesday.
Caledonia Mining declares quarterly dividend
Caledonia Mining declared a quarterly dividend of 14 US cents per share on Tuesday.
Plexus inks new agreement with Schlumberger
Oil and gas engineering services company Plexus announced an agreement with Schlumberger (SLB) on Tuesday, superseding a prior surface production wellhead licence and replacing it with a broader arrangement.
URU pushes repayment date on Boothbay convertible loan
URU Metals has extended the repayment date for its convertible loan from Boothbay Absolute Return Strategies, it announced on Tuesday, to 28 February.
Plant Health Care nematicide gets approval in Brazil
Crop peptide specialist Plant Health Care announced on Tuesday that its nematicide product TEIKKO has received federal approval in Brazil, ahead of a commercial launch for the upcoming 2025 soybean growing season.
Proteome launches San Diego lab operations
Proteomics services provider Proteome Sciences announced the installation and start of operations at its new laboratory in San Diego, California, on Tuesday.
Genedrive confirms £0.6m equity prepayment drawdown
Genedrive confirmed a planned £0. 6m drawdown as part of its £5m equity prepayment facility on Tuesday, which it initially disclosed on 31 March 2023.
Zanaga extends repayment data on Glencore loan
Zanaga Iron Ore Company announced on Tuesday that it has agreed with Glencore to extend the repayment date of its loan facility.
Maher Masoud starts as MaxCyte president, CEO
MaxCyte confirmed the appointment of Maher Masoud as its new president and chief executive officer on Tuesday, effective from 1 January.
Novacyt taps Steve Gibson for CFO
Biotechnology group Novacyt has appointed Steve Gibson to the role of chief financial officer with immediate effect.
Angle locks in $250,000 contract with Eisai
Liquid biopsy company Angle has locked in a $250,000 contract with global pharmaceutical company Eisai to deliver circulating tumour cell analysis in a pilot study.
hVIVO secures £6.3m contract with biotech client
Infectious and respiratory disease study group hVIVO has inked a £6. 3m contract with an unnamed biotechnology client to test an antiviral candidate using its common cold virus human challenge study model.